Introduction
Simian immunodeficiency viruses (SIVs) are primate lentiviruses that share a common ancestry with human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) (Doolittle, 1989; Peeters et al., 1991) . SIV has been isolated from different species of immunodeficient macaques (SIVmac) in several primate centres (Daniel et al., 1985) . However, macaques are apparently not infected with SIV in the wild (Lowenstine et al., 1986) . In contrast, several species of African primates are naturally infected with SIV. In these African monkeys SIV infection is apparently non-pathogenic, whereas infection of Asian macaques leads to fatal simian AIDS (Murphey-Corb et al., 1986) . At least three genetically distinct African SIV strains have been isolated: SlVsm from sooty mangabeys (Cercocebus atys) (Fultz et al., 1986; Murphey-Corb et al., 1986) , SIVag m from African green monkeys (Cercopithecus aethiops) Baier et al., 1990) and SlVmn d from mandrills (Papio sphinx) (Tsujimoto et al., 1988) . Several studies indicate that up to 50 ~ of the African green monkeys are infected with SIV Lowenstine et al., 1986) . Recently, a lentivirus has been identified in wild chimpanzees (Pan troglodytes troglodytes) (SlVepz) (Peeters et al., 1989; Huet et al., 1990) . Whereas SIVmac is 0001-0807 © 1992 SGM closely related to HIV-2, and SIVcp z to HIV-1 (Huet et al., 1990) , SIVag m and SIVmn d appear both equidistant from both HIV-1 and HIV-2 (Gardner & Luciw, 1988) .
We have now studied various SIV strains for their susceptibility to inhibition by the novel HIV-l-specific reverse transcriptase (RT) inhibitors tetrahydro-imidazo [4,5, l-jk] [ 1,4]-benzodiazepin-2(1H)-one and -thione (TIBO) and the 1-(2-hydroxyethoxymethyl)-6-(phenylthio)-thymine (HEPT) derivatives (Pauwels et al., 1990; Baba et al., 1991 ; Debyser et al., 1991) . In contrast to the classical RT inhibitors such as phosphonoformic acid (PFA) and 3'-azido-3'-deoxythymidine (AZT) 5'-triphosphate, TIBO and HEPT inhibit HIV-1 RT, but not HIV-2 RT. The more recently developed dipyridodiazepinones, pyridinones and bis(hetero-aryl)piperazines share this property (Merluzzi et al., 1990; Goldman et al., 1991; Romero et al., 1991) . The HIV-l-specific RT inhibitors are ineffective not only against HIV-2 RT, but also against the RTs of avian myeloblastosis virus, Moloney murine leukaemia virus, SIV [from macaques (SlVmac)] and feline leukaemia virus (Merluzzi et al., 1990; Debyser et al., 1991; Goldman et al., 1991) .
Here we report on the sensitivity of two SIVag m strains to the inhibitory effects of TIBO and HEPT at the level of either RT activity or virus-induced cytopathicity, or both.
Methods
Viruses. The HIV-I strains used in our studies were: strain HTLVIIIs (LAI) and strain RF, originating from a patient of Haitian descent (Starcich et al., 1986) , both obtained from R. C. Gallo, National Institutes of Health, Bethesda, Md., U.S.A. ; strain HE, isolated by us from a Belgian patient with AIDS, and strain NDK, a highly cytopathic strain (Spire et al., 1989) , obtained from J. C. Chermann (INSERM, Marseilles, France). The HIV-2 strain ROD (Clavel et al., 1986) was provided by L. Montagnier, Pasteur Institute, Paris, France and SIVma~251 (Franchini et al., 1987) was received from C. Bruck, SmithKline Beecham, Genval, Belgium. SlVa0m3 , a sequenced strain (Baler et al., 1990) , was a kind gift from R. Kurth, Paul Ehrlich Institut, Langen, Germany; SIVagmxYo. 1 and SIVmndGBl, both sequenced strains L0ke et aL, 1991 ; Tsujimoto et al., 1988) , were received from G. Hunsmann, Deutsches Primatenzentrum, G6ttingen, Germany. (Fig. 1) has been described by Pauwels et al. (1990) . For HEPT and its derivative E-EPU [5-ethyl-l-ethoxymethyl-6-(phenylthio) uracil] (Fig. 1 ), see Miyasaka et aL (1989) and Baba et aL (1991) . Stock solutions of all compounds were prepared in DMSO. The final DMSO concentration in the RT assays was less than 2~. 2',YDideoxyguanosine 5'-triphosphate (ddGTP) (Pharmacia) was directly dissolved in reaction buffer. For the antiviral assays AZT and R82150 were dissolved in culture medium.
Antiviral assays.
Cell viability of MT-4 or MOLT-4 cells infected at 100 times the CCIDs0 (50% cell culture infective dose) of HTLV-IIIs, HIV'2ROD, SIVmae251 or SIVmn0GB1 was determined by a tetrazolium colorimetric method (MTT), as described previously (Pauwels et aL, 1988) . This method was used to determine the 50% inhibitory concentrations (ICso) and 50 ~ cytotoxic concentrations (CC50) of the compounds. Antiviral efficacy in MOLT-4 cells, infected with SlVagra 3 at 100 times the CCIDso, was evaluated microscopically by quantifying the c.p.e. Cytotoxicity in the MOLT-4 cells was determined by trypan blue exclusion.
RT sources. Virion-derived RT was obtained from the cell culture fluids of cell lines infected with HIV or SIV, i.e. HUT-78/HTLV-IIIs, MOLT/HTLV-IIIRF, MOLT/HIV-2RoD, MOLT/SIVa0m3, MOLT/ SIVagmTVO.l, MOLT/SIVmndGB1, CEM/HIV-1NDg, MOLT/HIV-1HE and MT-4/SIVmac251. The cells were clarified by low-speed centrifugation (10 min at 140 g). Supernatants were filtered through a 0.22 lxm Millex GV filter (Millipore). Virus particles were subsequently pelleted by centrifugation at 100000 g for 2 h. Pellets were resuspended in a solution containing 5 mM-Tris-HCl pH 8-1, 1 mM-DTT, 0.1 ~ (w/v) Triton X-100 and 0.5 bI-KCI. Resuspended pellets were stored in aliquots at -70 °C until use.
RT assays. The RT reaction mixture (50 ~tl) contained 50 mM-Tris-HCI pH 8.1, 10 mM-MgCI2, 100 mM-KC1, 2-2 mM-DTT and 0.05~ (w/v) Triton X-100. The template/primer [poly(C).oligo(dG)~2_ls] (Pharmacia) was used at a concentration of 65 ~tg/ml. Tritium-labelled dGTP was purchased from Amersham and used at a final concentration of 2.5 p.M. Specific activity was 11 Ci/mmol (1 Ci = 37 GBq). of the different enzyme preparations, the reaction mixture was incubated for 1 h at 37 °C. The incorporation rate was determined by a standard TCA precipitation procedure using Whatman GF/C glass fibre filters (Whatman) and liquid scintillation counting (ReadyProtein, Beckman). Expression ofRT. Escherichia coil JMI09 containing native or mutant pKRT2 were grown to late logarithmic phase (4 h) at 37 °C in Luria broth with 500 mg/l ampicillin. Subsequently, transcription from the trc promoter was induced with 0-5 mM-IPTG for 6 h. Cells were then pelleted, washed with buffer (20 mM-Tris-HCl pH 8.2, 1 mM-EDTA, 75 mM-NaCI) and frozen at -20 °C. After thawing, cells were lysed in a buffer solution containing 500 mM-NaC1, 50 mM-Tris-HCl pH 8-0, 2 mM-EDTA, 5 mM-DTT, 1 mM-PMSF, 0.1% (w/v) Triton X-100, 1 mg/ml lysozyme and 10% glycerol, then sonicated and centrifuged (D'Aquila & Summers, 1989) . The snpernatant of the E. coil lysate was diluted 10-fold in a solution containing 5 mM-Tris-HCl pH 8.1, 1 mM-DTT, 0-1% Triton X-100 and 0.5 M-KC1, and added to the RT reaction mixture.
Results

Susceptibility of RT from different SIV and HIV strains to TIBO
The (virion-derived) RTs obtained from the culture fluid of various T cell lines infected with different HIV or SIV strains were examined for their sensitivity to TIBO R82150 and the chain terminator ddGTP (Table 1 ). The RTs from the different HIV-1 strains proved susceptible to R82150. Their IC50 ranged from 0-1 ~tM for the RF strain up to 2.5 ~tM for the clinical HE isolate. The RTs of HIV-2ROD and the closely related SIVmacZ51 were not 
Anti-SIVo~m activity in cell culture
Next, we examined the effect of TIBO R82150 on SIVagm-induced cytopathicity in cell culture (Table 2) . SIVaQm3 induced a syncytial c.p.e, in MOLT-4 cells that could be blocked by TIBO R82150 at micromolar concentrations (ICs0 11 p.M), far below its cytotoxic concentration. SIVagmTVO. 1 did not induce any cytopathic effect in MOLT-4 cells. SIVmac2s~, HIV-2ROD and SIVm,d~B~ were not susceptible to TIBO inhibition at concentrations up to 350 p-M. SIVa0m3 cytopathicity was blocked by the HEPT derivative E-EPU at a concentration of 0.6 p-M (Table 2) and by R86183, a new highly potent TIBO congener, at a concentration of 0.7 p.M (data not shown).
Kinetic studies with SIVoom3-derived RT
Steady-state kinetics experiments were performed with virion-derived SlWagm3 RT in 15 min assays. The incorporation of [3H]dGMP was linear for at least 1 h. The concentration of substrate (dGTP) was varied, whereas the concentration of the template/primer [poly-(C). oligo(dG)l z-is] was at a saturating concentration of 65 p-g/ml. The K m value of the SIVaom3 RT for dGTP was 2-5 p-M, which corresponds closely to the Km (3 p-M) that we determined for HIV-l(RF)-derived RT. Inhibition of SlWaom3 RT by ddGTP as well as R82150 was competitive with respect to the natural substrate dGTP. Lineweaver-Burk transformation plots for inhibition by ddGTP and R82150 are shown in Fig. 2(a) and Fig. 2(b) , respectively. From a Dixon transformation plot the K~ of the enzyme for R82150 was estimated at 170 p-M (data not shown).
Identification of amino acids involved in TIBO binding to RT
Three different approaches have recently led to the identification of the amino acids involved in HIV-Ispecific RT binding of TIBO and TIBO-like type compounds. Nunberg et al. (1991) were able to select pyridinone-resistant HIV-1 mutants following passage of the virus in the presence of the compound. Sequence analysis indicated Y~8~C as the major mutation. Photoaffinity-labelling experiments with dipyridodiazepinones pointed to Y~ 81 and Y~ 88 as the crucial amino acids involved in inhibitor binding (Cohen et al., 1991) . Sitedirected mutagenesis of the amino acids in the conserved domains of HIV-1 RT to their HIV-2 counterparts confirmed the crucial role of Yt8t and Y188 in the Alignments were based on sequences reported in Human Retroviruses and AIDS (Myers, 1990) . The highly conserved YMDD locus is flanked by variable amino acids 181 and 188, involved in the binding of TIBO and TIBO-like derivatives. (Fig. 3) , we inferred position 188 to be more important in determining sensitivity/resistance to TIBO than position 181, and, therefore, the role of Y188 was further examined by sitedirected mutagenesis at this position (Table 3) . Substitution of Y~88 by L, the amino acid in HIV-2 and SIVma c RT, induced nearly complete resistance to R82150 and E-EPU, without affecting enzymatic activity. No crossresistance was observed for PFA (data not shown). Substitution of Y~88 by W, the amino acid of SIVag m, and F, the amino acid of SIVm.d, reduced the enzymatic activity by four-and 10-fold, whereas the sensitivity to TIBO and HEPT was decreased by 10-and fourfold, respectively. The sensitivity of the YlsaW mutant to E-EPU decreased 10-fold, but the YlasF mutation did not decrease sensitivity.
Discussion
To our knowledge, this is the first report of sensitivity of a non-HIV-1 retrovirus to TIBO and TIBO-like derivatives. Replication of SIVagm3 in cell culture was inhibited by R82150 and E-EPU at micromolar concentrations, far below the cytotoxicity threshold. Inhibition was due to an interaction with RT. In contrast to the two strains of SIVag m examined, SIVmn d was insensitive to the TIBO and HEPT derivatives.
In previous studies it was found that TIBO and TIBOlike compounds inhibit HIV-1 RT non-competitively with respect to the natural substrate (Debyser et al., 1991; Goldman et al., 1991; Merluzzi et al., 1991) . However, for HEPT itself, which is a relatively weak inhibitor of HIV-1 RT, we found a competitive type of inhibition (Debyser et al., 1992a) . RT inhibition by E-EPU was found to be non-competitive with respect to dGTP but competitive with respect to dTTP (Baba et al., 1991) . Here, we show that the relatively weak inhibition of SIVagm3 by TIBO is also competitive with respect to the substrate. Both findings point to the possibility of the existence of two TIBO binding sites at the HIV (SIV) RT: a high-affinity binding site and a low-affinity binding site. At the SIV RT, TIBO would interact solely with the high-affinity binding site, thus resulting in competitive inhibition. At the HIV RT, TIBO would interact with both the high-affinity and low-affinity binding sites, thus resulting in non-competitive inhibition.
We recently observed cooperative behaviour of the heterodimeric p66/p51 with regard to dGTP. TIBO R82150 interfered with this cooperative interaction (Debyser et al., 1992b) . Assuming that there are two binding sites for TIBO, they may be located on p66 and p51. The highly potent TIBO derivatives would be able to interact with both sites, whereas the less potent inhibitors (HEPT) would interact with only one binding site (with high affinity), likely to be located on the p66 subunit. Similarly, SIVa0 m RT which has a reduced affinity for TIBO as compared to HIV-1 RT may permit TIBO to interact only with the high-affinity site.
Ytst and Y~88 represent two amino acids that are critically involved in the binding of the HIV-l-specific inhibitors to RT. The Y~saL mutation caused a virtually total resistance to TIBO and HEPT, as attested by sitedirected mutagenesis of HIV-1 RT and the natural insensitivity of HIV-2 and SIVm~c strains. Substitution of Y~a8 by the aromatic amino acid residues W and F, which are the respective amino acids at position 188 in SIVag m and SlVmn d RTs, caused a marked decrease in enzymatic activity in contrast to the mutant enzyme Y~ssL. Mutations Y~aaW and YtssF, however, conferred only minor resistance to HIV-1 RT for TIBO and HEPT. The weak sensitivity of the RT of SlVaam3 and SIVagmTVO-~ is likely to be due to V~81, since a Y181I mutation has been found to cause partial resistance to TIBO and HEPT. The natural resistance of SIVmndGB1 for TIBO and HEPT cannot be explained by amino acid alignments in the conserved domain 180 to 190 (Fig. 3) : SlVmndGal has a Y at position 181 and the Y188F mutation did not decrease the sensitivity of RT to TIBO and HEPT considerably. Other amino acids may be responsible for this natural resistance. The fact that aromatic amino acid residues at position 188 seem interchangeable for TIBO and HEPT interaction makes a hydrogen bond formation between the hydroxyl group of tyrosine 188 and the inhibitor unlikely. Binding at this site seems to be based on interaction between ~-electron systems.
Our report on the sensitivity to TIBO of a non-HIV-1 retrovirus, SIVagm, warrants further research regarding the relationship between the respective RTs. The questions remain whether the differential effects of TIBO derivatives on different SIV strains can be explained solely by the absence or existence of a functional TIBO site on some of them, and whether the existence of a functional TIBO site implies functional differences between the different RTs.
Before the present findings, it was not possible to propose antiviral efficacy studies of TIBO and TIBOlike derivatives in the intact animal, because this range of compounds was active against HIV-1 only, and only humans and chimpanzees are susceptible to infection by HIV-1. A primate model is now at hand, using African green monkeys which are among the commonly available monkey species, or other monkeys that might be experimentally susceptible to TIBO-sensitive SIVa0m. Sensitivity in the monkey model could be improved if SIV strains could be found with higher in vitro sensitivity than the few strains studied here, or could be constructed by recombinant DNA technology.
